DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells

DNA Repair

Volumn 2, Issue 1, 2003, Pages 73-89

  Massey, Andrew ^b   Offman, Judith ^a   Macpherson, Peter ^a   Karran, Peter ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b RiboTargets Ltd   (United Kingdom)

Author keywords

Cisplatin; E. coli; MMR

Indexed keywords

CISPLATIN; DNA; MESSENGER RNA; PROTEIN; PROTEIN MMR; UNCLASSIFIED DRUG; MICROSATELLITE DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DNA CONTENT; DNA METHYLATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MISMATCH REPAIR; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; CARCINOMA; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; OVARY TUMOR; PHYSIOLOGY;

CARCINOMA; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI; FEMALE; HUMANS; MICROSATELLITE REPEATS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0346451137     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-7864(02)00187-8     Document Type: Article

References (39)

1. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer. 34:1998;1535-1542.
2. Koberle B., Masters J.R.W., Hartley J.A., Wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 9:1999;273-276.
3. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R.D., Howell S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:1996;4881-4886.
4. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 58:1998;3579-3585.
5. Anthoney D.A., McIlwrath A.J., Gallagher W.M., Edlin A.R.M., Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumour cells. Cancer Res. 56:1996;1374-1381.
6. Gong J.G., Costanzo A., Yang H.-Q., Melino G., Kaelin Jr W.G., Levrero M., Wang J.Y.J. The tyrosine kinase c-Abl regulates p73 in apoptoic response to cisplatin-induced DNA damage. Nature. 399:1999;806-809.
7. Harfe B.D., Jinks-Robertson S. DNA mismatch repair and genetic instability. Annu. Rev. Genet. 34:2000;359-399.
8. 6-methylguanine residues in E. coli DNA. Nature. 296:1982;868-869.
9. Fram R.J., Cusick P.S., Wilson J.M., Marinus M.G. Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage. Mol. Pharmacol. 28:1985;51-55.
10. 6-methylguanine and the cytotoxicity of methylating agents. Mutat. Res. 462:2000;71-82.
11. Aquilina G., Hess P., Fiumicino S., Ceccotti S., Bignami M. A mutator phenotype characterises one of two complementation groups in human cells tolerant to methylation damage. Cancer Res. 55:1995;2569-2575.
12. 6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells. J. Biol. Chem. 272:1997;28596-28606.
13. O'Driscoll M., Martinelli S., Ciotta C., Karran P. Combined mismatch and nucleotide excision repair defects in a human cell line: mismatch repair processes methylation but not UV- or ionising-induced DNA damage. Carcinogenesis. 20:1999;799-804.
14. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57:1997;850-856.
15. Johnsson A., Zeelenberg I., Min Y., Hilinski J., Berry C., Howell S.B., Los G. Identification of genes differentially expressed in association with acquired cisplatin resistance. Brit. J. Cancer. 83:2000;1047-1054.
16. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characteristaion of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:1987;414-418.
17. Aquilina G., Ceccotti S., Martinelli S., Soddu S., Crescenzi M., Branch P., Karran P., Bignami M. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea. Clin. Cancer Res. 6:2000;671-680.
18. Branch P., Masson M., Aquilina G., Bignami M., Karran P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumour cells. Oncogene. 19:2000;3138-3145.
19. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R.L., Dayton S.H., Herrera G.E., Yamamuro T., Kotoura Y., Sasaki M.S., Little J.B., Weichselbaum R.R., Ishizaki K., Yandell D.W. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52:1992;6194-6199.
20. Koberle B., Grimaldi K.A., Sunters A., Hartley J.A., Kelland L.R., Masters J.R.W. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer. 70:1997;551-555.
21. Oda S., Humbert O., Fiumicino S., Bignami M., Karran P. Efficient repair of A/C mismatches in mouse cells deficient in long-patch mismatch repair. EMBO J. 19:2000;1711-1718.
22. Wei Q., Bondy M.L., Mao L., Guan Y., Cheng L., Cunningham J., Fan Y., Bruner J.M., Yung W.K.A., Levin V.A., Kyritsis A.P. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res. 57:1997;1673-16777.
23. Dietmaier W., Wallinger S., Bocker T., Kullmann F., Fishel R., Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 57:1997;4749-4756.
24. Humbert O., Fiumicino S., Aquilina G., Branch P., Oda S., Zijno A., Karran P., Bignami M. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis. 20:1999;205-214.
25. Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., Jessup J.M., Koldner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumours and mismatch repair-defective human tumour cell lines. Cancer Res. 57:1997;808-811.
26. Umar A., Boyer J.C., Thomas D.C., Nguyen D.C., Risinger J.I., Boyd J., Ionov Y., Perucho M., Kunkel T.A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem. 269:1994;14367-14370.
27. Papadopoulos N., Nicolaides N.C., Liu B., Parsons R., Lengauer C., Palombo F., D'Arrigo A., Markowitz S., Willson J.K.V., Kinzler K.W., Jiricny J., Vogelstein B. Mutations of GTBP in genetically unstable cells. Science. 268:1995;1915-1917.
28. Hoang J.-M., Cottu P.H., Thuille B., Salmon R.J., Thomas G., Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 57:1997;300-303.
29. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R.D., Boland C.R., Koi M., Fishel R., Howell S.B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:1996;3087-3090.
30. Strathdee G., MacKean M.J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 18:1999;2335-2341.
31. Fleisher A.S., Esteller M., Wang S., Tamura G., Suzuki H., Yin J., Zou T.-T., Abraham J.M., Kong D., Smolinski K.N., Shi Y.-Q., Rhyu M.-G., Powell S.M., James S.P., Wilson K.T., Herman J.G., Meltzer S.J. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 59:1999;1090-1095.
32. Esteller M., Levine R., Baylin S.B., Ellenson L.H., Herman J.G. MLH1 Promoter hypermethylation is associated with the microsatellite instablility phenotype in sporadic endometrial carcinomas. Oncogene. 16:1998;2413-2417.
33. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., Markowitz S., Willson J.K.V., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hmlh1 promoter hypermethylation in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6870-6875.
34. Samimi G., Fink D., Varki N.M., Husain A., Hoskins W.J., Alberts D.S., Howell S.B. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res. 6:2000;1415-1421.
35. Hamaguchi K., Godwin A.K., Yakushiji M., O'Dwyer P.J., Ozols R.F., Hamilton T.C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian carcinoma cell lines. Cancer Res. 53:1993;5225-5232.
36. Mamenta E.L., Poma E.E., Kaufmann W.K., Delmastro D.A., Grady H.L., Chaney S.G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 54:1994;3500-3505.
37. 2′ C) EMBO J. 20:2001;4287-4298.
38. Vaisman A., Masutani C., Hanaoka F., Chaney S.G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase η Biochemistry. 39:2000;4575-4580.
39. Ohashi E., Ogi T., Kusumoto R., Iwai S., Masutani C., Hanaoka F., Ohmori H. Error-prone bypass of certain DNA lesions by the human DNA polymerase κ Genes Dev. 14:2000;1589-1594.